Quick filters
- New Data for Jakafi® (ruxolitinib) to Be Presented at the 2012 American Society of Hematology Annual Meeting Business Wire | Friday December 7, 2012 4:05PM
- Incyte to Present at the Oppenheimer 23rd Annual Healthcare Conference Business Wire | Wednesday November 28, 2012 8:00AM
- Incyte to Present at the 24th Annual Piper Jaffray Healthcare Conference Business Wire | Monday November 19, 2012 8:00AM
- Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis Business Wire | Thursday November 15, 2012 8:00AM
- Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis PR Newswire | Tuesday November 13, 2012 4:01PM
- Incyte to Present at the Jefferies 2012 Global Healthcare Conference (London) Business Wire | Monday November 5, 2012 8:00AM
- Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs Business Wire | Thursday November 1, 2012 7:00AM
- Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer Business Wire | Monday October 22, 2012 8:00AM
- Incyte to Report Third Quarter 2012 Financial Results on November 1 Business Wire | Tuesday October 9, 2012 8:00AM
- The biggest R&D spenders: Where innovation pays off Globe and Mail | Tuesday October 2, 2012 8:11PM
- National Myelofibrosis Awareness Day to Launch on September 20 Business Wire | Wednesday September 19, 2012 4:30PM
- Jakavi® (ruxolitinib) First Medication to Receive European Commission Approval to Treat Patients with Myelofibrosis Business Wire | Tuesday August 28, 2012 1:30AM
- Incyte to Present at Upcoming Investor Conferences Business Wire | Thursday August 23, 2012 4:10PM
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation PR Newswire | Friday August 3, 2012 8:30AM
- Incyte to Present at the 32nd Annual Canaccord Genuity Growth Conference Business Wire | Friday August 3, 2012 8:00AM
- CORRECTING and REPLACING Incyte Reports 2012 Second-Quarter Financial Results; Updates Shareholders on Launch of Jakafi and Lead Clinical Programs Business Wire | Thursday August 2, 2012 8:05PM
- Incyte to Report Second Quarter 2012 Financial Results on August 2 Business Wire | Monday July 16, 2012 4:10PM
- Incyte to Present at the JMP Securities 7th Annual Healthcare Conference Business Wire | Tuesday June 26, 2012 8:00AM
- Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis PR Newswire | Friday June 8, 2012 11:12AM
- Incyte Presents Results from a Phase I Trial of INCB024360, a Novel Oral Inhibitor of Indoleamine Dioxygenase-1 (IDO1), at ASCO Business Wire | Monday June 4, 2012 4:05PM
Live Discussion of INCY on StockTwits